BRAF and melanoma: Two of them demonstrated that, after treatment with two commonly used BRAF inhibitors (vemurafenib and dabrafenib), the EVs released by resistant melanoma cells contained factors linked to melanoma resistance and BRAF inhibitors, such as miR211-5p and PDGFR.